An FDA approved neurokinin-1 receptor antagonist is effective in reducing intraabdominal adhesions when administered intraperitoneally, but not orally - Lim, R; Morrill, J M; Prushik, S G; Reed, K L; Gower, A C; Leeman, S E; Stucchi, A F; Becker, J M (J Gastrointest Surg, 2008)